I have come to grips with the notion that all is not right with Isradipine. I have also come to grips with not getting a response from IR about Cmax issues with our soon to be presented drug application. Now these issues as I see them, are juxtaposed with common stock purchases by the CEO and conversion of preferred to common by JT which are usually positives. This leaves me wanting to hit something. So instead I will just follow the money and humbly wait for the next shoe to drop.